实用肝脏病杂志 ›› 2026, Vol. 29 ›› Issue (3): 450-453.doi: 10.3969/j.issn.1672-5069.2026.03.033

• 肝血管瘤 • 上一篇    下一篇

肝动脉栓塞术与血管瘤剥除术治疗肝血管瘤患者疗效比较研究*

徐道秀, 王芳, 贺祥昆, 葛晨   

  1. 214000 江苏省无锡市 解放军联勤保障部队第九○四医院普通外科(徐道秀,贺祥昆,王芳);东南大学附属中大医院无锡分院/无锡市锡山人民医院普通外科(葛晨)
  • 收稿日期:2025-11-17 出版日期:2026-05-10 发布日期:2026-05-18
  • 通讯作者: 贺祥昆,E-mail:Hexiangkun1003@126.com
  • 作者简介:徐道秀,女,35岁,大学本科。E-mail:18861606265@163.com
  • 基金资助:
    *江苏省自然科学基金资助项目(编号:BK20210687)

Transarterial embolization and hemangioma enucleation in the treatment of patients with hepatic hemangioma

Xu Daoxiu, Wang Fang, He Xiangkun, et al   

  1. Department of General Surgery, 904th Hospital, Joint Logistics Support Force, Wuxi 214000, Jiangsu Province, China
  • Received:2025-11-17 Online:2026-05-10 Published:2026-05-18

摘要: 目的 探讨肝动脉栓塞术(TAE)与血管瘤剥除术治疗肝血管瘤(HH)患者的疗效。方法 2022年3月~2025年3月我院收治的HH患者93例,其中42例接受TAE治疗,另51例接受血管瘤剥除治疗。应用视觉模拟评分法(VAS)评估术后24 h疼痛程度。结果 93例HH患者均顺利完成手术;TAE组手术时间、术中出血量和住院日分别为(59.7±14.8)min、(10.3±2.7)mL和(4.1±1.9)d,均显著短于或少于血管瘤剥除组【分别为(124.5±28.6)min、(472.5±53.9)mL和(9.5±1.8)d,P<0.05】,但两组术后24 h VAS评分【(4.2±1.3)分对(4.7±1.5)分】无显著性差异(P>0.05);在术后72 h,血管瘤剥除术组血清ALT和AST水平分别为(134.5±9.1)U/L和(91.2±8.4)U/L,均显著高于TAE组【分别为(82.6±20.8)U/L和(63.1±11.6)U/L,P<0.05】;术后,两组胆管炎、切口感染和肝区疼等不良事件发生率(28.6%对23.5%,P>0.05)比较无显著性差异。结论 采取TAE或血管瘤剥除术治疗HH患者均可获得良好的治疗效果,临床可根据肿瘤情况和技术力量选择进行。

关键词: 肝血管瘤, 肝动脉栓塞术, 血管瘤剥除术, 治疗

Abstract: Objective The aim of this study was to investigate transarterial embolization (TAE) and hemangioma enucleation (HE) in the treatment of patients with hepatic hemangioma (HH). Methods 93 patients with HH were recruited in our hospital between March 2022 and March 2025, and TAE was conducted in 42 cases and HE was performed in another 51 cases. Pain at 24 hours post-surgery was assessed by using visual analog scale (VAS). Results Both TAE and HE were successfully completed in the two groups; operation time, intraoperative blood loss and hospital stay in TAE group were (59.7±14.8)min, (10.3±2.7)mL and (4.1±1.9)d,all significantly shorter or less than [(124.5±28.6)min, (472.5±53.9)mL and (9.5±1.8)d,respectively, P<0.05] in HE group, while there was no significant difference as respect to VAS scores at 24 hours after operation [(4.2±1.3) vs. (4.7±1.5)] in the two groups (P>0.05); by 72 hours after surgery, serum ALT and AST levels in HE group were (134.5±9.1)U/L and(91.2±8.4)U/L, both significantly higher than [(82.6±20.8)U/L and (63.1±11.6)U/L, respectively, P<0.05] in TAE group; post-operationally, incidences of complications, such as cholangitis, infection and right upper quadrant pain, in the two groups(28.6% vs. 23.5%, P>0.05) were not significantly different. Conclusion We believe that both TAE and HE could be performed in patients with HH, and clinicians should make choice based both HH status and technical proficiency.

Key words: Hepatic hemangioma, Transarterial embolization, Hemangioma enucleation, Therapy